Acquired epilepsy is a form of the neurological disorder that results from other conditions such as stroke, infections, and traumatic brain injury.
The company announced this week the expansion of a genetic testing program for US patients with inherited retinal disease that it has run with partners since 2017.
Evogen's protein biomarker-based test is designed to stratify actively seizing patients from those who have not experienced a recent seizure.
Free genetic testing on a broad gene panel is available to children, from birth to five years old, if they've had an unprovoked seizure.
The effort could lead to Metafora's flow cytometry-based assay becoming the standard of care for diagnosing the disease in France.
Irish rare disease research center FutureNeuro is partnering with software vendor Congenica to bring sequencing to the point of care for genetic epilepsies.
Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.
The company is developing an epilepsy test based on inflammatory proteins in patient blood that is intended for ruling out patients with seizure-like symptoms.
The company plans to release its first product in this area, a blood-based proteomic diagnostic for epilepsy, as a laboratory-developed test next year.
The test, named EvoScore START, measures a panel of blood-based protein biomarkers to distinguish between epileptic seizures and other similar events.